probenecid has been researched along with Disease Exacerbation in 8 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Development of autosomal dominant polycystic kidney disease (ADPKD) involves renal epithelial cell abnormalities." | 5.91 | Probenecid slows disease progression in a murine model of autosomal dominant polycystic kidney disease. ( Arkhipov, SN; Harris, PC; Ilatovskaya, DV; Pavlov, TS; Potter, DL; Sultanova, RF, 2023) |
| "Although the clinical implication of hyperuricemia in chronic kidney disease has been an issue of active debate, recent data suggested a causative role of uric acid (UA) in the development of renal disease." | 3.88 | Hyperuricemia and Progression of Chronic Kidney Disease: Role of Phenotype Transition of Renal Tubular and Endothelial Cells. ( Kang, DH, 2018) |
| " Dose-dependent asymptomatic proteinuria (39%) and serum creatinine elevation (24%) were the most common adverse events thought to be related to cidofovir." | 2.69 | Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. ( Hardy, WD; Holland, GN; Ives, DV; Jaffe, HS; Johnson, M; Kemper, CA; Kramer, F; Kuppermann, BD; Lalezari, JP; Lewis, RA; McKinley, GF; Nelson, R; Northfelt, DW; Ruby, AE; Simon, GL; Stagg, RJ; Weinberg, DV; Wolitz, RA; Youle, M, 1998) |
| "Although gout is one of the most common forms of inflammatory arthritis, it has been relatively neglected until recently." | 2.55 | Major unanswered questions in the clinical gout field. ( Stamp, LK, 2017) |
| "Development of autosomal dominant polycystic kidney disease (ADPKD) involves renal epithelial cell abnormalities." | 1.91 | Probenecid slows disease progression in a murine model of autosomal dominant polycystic kidney disease. ( Arkhipov, SN; Harris, PC; Ilatovskaya, DV; Pavlov, TS; Potter, DL; Sultanova, RF, 2023) |
| "These results support reactive gliosis as a means of striatal compensation for dopamine loss." | 1.32 | Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease. ( Beales, M; Dervan, AG; McBean, GJ; Meredith, GE; Meshul, CK; Moore, C; Snyder, AK; Totterdell, S, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Arkhipov, SN | 1 |
| Potter, DL | 1 |
| Sultanova, RF | 1 |
| Ilatovskaya, DV | 1 |
| Harris, PC | 1 |
| Pavlov, TS | 1 |
| Hainz, N | 1 |
| Wolf, S | 1 |
| Beck, A | 1 |
| Wagenpfeil, S | 1 |
| Tschernig, T | 1 |
| Meier, C | 1 |
| Kang, DH | 1 |
| Stamp, LK | 1 |
| Carta, AR | 1 |
| Carboni, E | 1 |
| Spiga, S | 1 |
| Dervan, AG | 1 |
| Meshul, CK | 1 |
| Beales, M | 1 |
| McBean, GJ | 1 |
| Moore, C | 1 |
| Totterdell, S | 1 |
| Snyder, AK | 1 |
| Meredith, GE | 1 |
| Lalezari, JP | 1 |
| Holland, GN | 1 |
| Kramer, F | 1 |
| McKinley, GF | 1 |
| Kemper, CA | 1 |
| Ives, DV | 1 |
| Nelson, R | 1 |
| Hardy, WD | 1 |
| Kuppermann, BD | 1 |
| Northfelt, DW | 1 |
| Youle, M | 1 |
| Johnson, M | 1 |
| Lewis, RA | 1 |
| Weinberg, DV | 1 |
| Simon, GL | 1 |
| Wolitz, RA | 1 |
| Ruby, AE | 1 |
| Stagg, RJ | 1 |
| Jaffe, HS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)[NCT00000142] | Phase 2/Phase 3 | 64 participants (Actual) | Interventional | 1994-04-30 | Completed | ||
| HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol[NCT00000799] | 100 participants | Interventional | Completed | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00000142)
Timeframe: All patients enrolled will be followed until a common study closing date
| Intervention | participants (Number) | ||
|---|---|---|---|
| mortality | progression | va loss of 15 letters | |
| Cidofovir (High Dose) | 3 | 5 | 2 |
| Cidofovir (Low Dose) | 7 | 17 | 6 |
| Treatment Deferral | 6 | 20 | 4 |
1 review available for probenecid and Disease Exacerbation
| Article | Year |
|---|---|
Major unanswered questions in the clinical gout field.
Topics: Allopurinol; Benzbromarone; Colchicine; Disease Progression; Febuxostat; Gout; Gout Suppressants; Hu | 2017 |
2 trials available for probenecid and Disease Exacerbation
5 other studies available for probenecid and Disease Exacerbation
| Article | Year |
|---|---|
Probenecid slows disease progression in a murine model of autosomal dominant polycystic kidney disease.
Topics: Adenosine Triphosphate; Animals; Cysts; Disease Models, Animal; Disease Progression; Female; Humans; | 2023 |
Probenecid arrests the progression of pronounced clinical symptoms in a mouse model of multiple sclerosis.
Topics: Animals; Cell Count; Disease Models, Animal; Disease Progression; Mice; Mice, Inbred C57BL; Multiple | 2017 |
Hyperuricemia and Progression of Chronic Kidney Disease: Role of Phenotype Transition of Renal Tubular and Endothelial Cells.
Topics: Actins; Animals; Antioxidants; Capillaries; Disease Progression; Endothelial Cells; Epithelial-Mesen | 2018 |
The MPTP/probenecid model of progressive Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Chromatography, High Pressu | 2013 |
Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biological Transport; Cell Count; | 2004 |